A study of CA4P in combination with Opdivo evaluating the combination in advanced melanoma patients who have not responded to currently approved treatments
Latest Information Update: 02 Mar 2022
At a glance
- Drugs Fosbretabulin (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
Most Recent Events
- 21 May 2018 New trial record